Effect of hypoxia on Ad5 infection, transgene expression and replication

Gene Therapy

Volumn 12, Issue 11, 2005, Pages 902-910

  Shen, B H ^a   Hermiston, T W ^a  

^a BAYER AG   (Germany)

Author keywords

Ad replication; Adenovirus type 5; Cancer; Hypoxia

Indexed keywords

ADENOVIRUS VECTOR; ALPHA INTEGRIN; ANTINEOPLASTIC AGENT; COXSACKIE VIRUS AND ADENOVIRUS RECEPTOR; E1A PROTEIN; LUCIFERASE;

ADENOVIRUS 5; ARTICLE; CANCER CELL; CELL CYCLE G1 PHASE; CELL CYCLE S PHASE; CELL GROWTH; CELLULAR DISTRIBUTION; CONTROLLED STUDY; CYTOMEGALOVIRUS; DRUG RECEPTOR BINDING; DRUG TRANSPORT; GENE EXPRESSION; GROWTH INHIBITION; HUMAN; HUMAN CELL; HYPOXIA; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN PROCESSING; TREATMENT INDICATION; VIRAL GENE DELIVERY SYSTEM; VIRUS REPLICATION;

ADENOVIRUS E1A PROTEINS; ADENOVIRUS INFECTIONS, HUMAN; ADENOVIRUSES, HUMAN; BLOTTING, WESTERN; CELL HYPOXIA; CELL LINE; G1 PHASE; GENE EXPRESSION REGULATION; GENE THERAPY; HUMANS; RECEPTORS, VIRUS; TRANSGENES; TUMOR CELLS, CULTURED; VIRUS REPLICATION;

ADENOVIRIDAE; COXSACKIEVIRUS; HUMAN ADENOVIRUS TYPE 5; HUMAN HERPESVIRUS 5;

EID: 20744442757     PISSN: 09697128     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.gt.3302448     Document Type: Article

References (57)

1. Williams DA, Smith FO. Progress in the use of gene transfer methods to treat genetic blood diseases. Hum Gene Ther 2000; 11: 2059-2066.
2. INGN 201. Ad-p53, Ad5CMV-p53, Adenoviral p53, INGN 101, p53 gene therapy - Introgen, RPR/INGN 201. BioDrugs 2003; 17: 216-222.
3. Swisher SG et al. Induction of p53-regulated genes and tumor regression in lung cancer patients after intratumoral delivery of adenoviral p53 (INGN 201) and radiation therapy. Clin Cancer Res 2003; 9: 93-101.
4. Buller RE et al. A phase I/II trial of rAd/p53 (SCH 58500) gene replacement in recurrent ovarian cancer. Cancer Gene Ther 2002; 9: 553-566.
5. Kirn D. Replication-selective oncolytic adenoviruses: virotherapy aimed at genetic targets in cancer. Oncogene 2000; 19: 6660-6669.
6. Hermiston T. Fighting fire with fire: attacking the complexity of human tumors with armed therapeutic viruses. Curr Opin Mol Ther 2002; 4: 334-342.
7. Semenza GL et al. Hypoxia, HIF-1, and the pathophysiology of common human diseases. Adv Exp Med Biol 2000; 475: 123-130.
8. Niinikoski J. Hyperbaric oxygen therapy of diabetic foot ulcers, transcutaneous oxymetry in clinical decision making. Wound Repair Regen 2003; 11: 458-461.
9. Zauner A, Daugherty WP, Bullock MR, Warner DS. Brain oxygenation and energy metabolism: part I - biological function and pathophysiology. Neurosurgery 2002; 51: 289-301; discussion 302.
10. Wouters BG et al. Hypoxia as a target for combined modality treatments. Eur J Cancer 2002; 38: 240-257.
11. Brown JM. The hypoxic cell: a target for selective cancer therapy - eighteenth Bruce F. Cain Memorial Award lecture. Cancer Res 1999; 59: 5863-5870.
12. Graeber TG et al. Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumours. Nature 1996; 379: 88-91.
13. Wouters BG et al. Modulation of cell death in the tumor microenvironment. Semin Radiat Oncol 2003; 13: 31-41.
14. Brown JM, Giaccia AJ. The unique physiology of solid tumors: opportunities (and problems) for cancer therapy. Cancer Res 1998; 58: 1408-1416.
15. Ratcliffe PJ, O'Rourke JF, Maxwell PH, Pugh CW. Oxygen sensing, hypoxia-inducible factor-1 and the regulation of mammalian gene expression. J Exp Biol 1998; 201 (Part 8): 1153-1162.
16. Giaccia A, Siim BG, Johnson RS. HIF-1 as a target for drug development. Nat Rev Drug Discov 2003; 2: 803-811.
17. Post DE, Van Meir EG. A novel hypoxia-inducible factor (HIF) activated oncolytic adenovirus for cancer therapy. Oncogene 2003; 22: 2065-2072.
18. Aebersold DM et al. Expression of hypoxia-inducible factor-1alpha: a novel predictive and prognostic parameter in the radiotherapy of oropharyngeal cancer. Cancer Res 2001; 61: 2911-2916.
19. Vukovic V et al. Hypoxia-inducible factor-1alpha is an intrinsic marker for hypoxia in cervical cancer xenografts. Cancer Res 2001; 61: 7394-7398.
20. Wenger RH et al. Hypoxia-inducible factor-1 alpha is regulated at the post-mRNA level. Kidney Int 1997; 51: 560-563.
21. Shenk T. Adenoviridae: the virus and their replication. In: Knipe D, Howley, PM (eds). Fields Virology. Lippincott Williams & Wilkins: Philadelphia, 2001, pp 2266.
22. Hewitt J, Anderson CW, Freimuth P. Adenovirus interaction with its cellular receptor CAR. Curr Top Microbiol Immunol 2003; 272: 331-364.
23. Bergelson JM et al. Isolation of a common receptor for Coxsackie B viruses and adenoviruses 2 and 5. Science 1997; 275: 1320-1323.
24. Triantafilou K, Takada Y, Triantafilou M. Mechanisms of integrin-mediated virus attachment and internalization process. Crit Rev Immunol 2001; 21: 311-322.
25. Wickham TJ, Mathias P, Cheresh DA, Nemerow GR. Integrins alpha v beta 3 and alpha v beta 5 promote adenovirus internalization but not virus attachment. Cell 1993; 73: 309-319.
26. Noutsias M et al. Human coxsackie-adenovirus receptor is colocalized with integrins alpha(v)beta(3) and alpha(v)beta(5) on the cardiomyocyte sarcolemma and upregulated in dilated cardiomyopathy: implications for cardiotropic viral infections. Circulation 2001; 104: 275-280.
27. Summerford C, Bartlett JS, Samulski RJ. AlphaVbeta5 integrin: a co-receptor for adeno-associated virus type 2 infection. Nat Med 1999; 5: 78-82.
28. Salone B et al. Integrin alpha3beta1 is an alternative cellular receptor for adenovirus serotype 5. J Virol 2003; 77: 13448-13454.
29. Dechecchi MC et al. Heparan sulfate glycosaminoglycans are receptors sufficient to mediate the initial binding of adenovirus types 2 and 5. J Virol 2001; 75: 8772-8780.
30. Hong SS et al. Enhancement of adenovirus-mediated gene delivery by use of an oligopeptide with dual binding specificity. Hum Gene Ther 1999; 10: 2577-2586.
31. Li E et al. Integrin alpha(v)beta1 is an adenovirus coreceptor. J Virol 2001; 75: 5405-5409.
32. Davison E et al. Adenovirus type 5 uptake by lung adenocarcinoma cells in culture correlates with Ad5 fibre binding is mediated by alpha(v)beta1 integrin and can be modulated by changes in beta1 integrin function. J Gene Med 2001; 3: 550-559.
33. Miyazawa N et al. Fiber swap between adenovirus subgroups B and C alters intracellular trafficking of adenovirus gene transfer vectors. J Virol 1999; 73: 6056-6065.
34. Goldsmith KT, Curiel DT, Engler JA, Garver Jr RI. Trans complementation of an E1A-deleted adenovirus with codelivered E1A sequences to make recombinant adenoviral producer cells. Hum Gene Ther 1994; 5: 1341-1348.
35. White JR et al. Genetic amplification of the transcriptional response to hypoxia as a novel means of identifying regulators of angiogenesis. Genomics 2004; 83: 1-8.
36. Ning W et al. Genome wide analysis of the endothelial transcriptome under short-term chronic hypoxia. Physiol Genomics 2004; 18: 70-78.
37. Amano H, Maruyama K, Naka M, Tanaka T. Target validation in hypoxia-induced vascular remodeling using transcriptome/metabolome analysis. Pharmacogenomics J 2003; 3: 183-188.
38. Hawkins LK, Lemoine NR, Kirn D. Oncolytic biotherapy: a novel therapeutic plafform. Lancet Oncol 2002; 3: 17-26.
39. Kanerva A, Hemminki A. Modified adenoviruses for cancer gene therapy. Int J Cancer 2004; 110: 475-480.
40. Kirn D, Niculescu-Duvaz I, Hallden G, Springer CJ. The emerging fields of suicide gene therapy and virotherapy. Trends Mol Med 2002; 8: S68-S73.
41. Post DE, Khuri FR, Simons JW, Van Meir EG. Replicative oncolytic adenoviruses in multimodal cancer regimens. Hum Gene Ther 2003; 14: 933-946.
42. Nettelbeck DM. Virotherapeutics: conditionally replicative adenoviruses for viral oncolysis. Anticancer Drugs 2003; 14: 577-584.
43. Hitt MM, Graham FL. Adenovirus E1A under the control of heterologous promoters: wide variation in E1A expression levels has little effect on virus replication. Virology 1990; 179: 667-678.
44. Schmaltz C, Hardenbergh PH, Wells A, Fisher DE. Regulation of proliferation-survival decisions during tumor cell hypoxia. Mol Cell Biol 1998; 18: 2845-2854.
45. Freyer JP, Sutherland RM. Proliferative and clonogenic heterogeneity of cells from EMT6/Ro multicellular spheroids induced by the glucose and oxygen supply. Cancer Res 1986; 46: 3513-3520.
46. Bellett AJ et al. Control functions of adenovirus transformation region E1A gene products in rat and human cells. Mol Cell Biol 1985; 5: 1933-1939.
47. Bellett AJ et al. Functions of the two adenovirus early E1A proteins and their conserved domains in cell cycle alteration, actin reorganization, and gene activation in rat cells. J Virol 1989; 63: 303-310.
48. Binley K et al. Hypoxia-mediated tumour targeting. Gene Therapy 2003; 10: 540-549.
49. Binley K et al. An adenoviral vector regulated by hypoxia for the treatment of ischaemic disease and cancer. Gene Therapy 1999; 6: 1721-1727.
50. Kaliberov SA et al. Adenovirus-mediated transfer of BAX driven by the vascular endothelial growth factor promoter induces apoptosis in lung cancer cells. Mol Ther 2002; 6: 190-198.
51. Goda N, Dozier SJ, Johnson RS. HIF-1 in cell cycle regulation, apoptosis, and tumor progression. Antioxid Redox Signal 2003; 5: 467-473.
52. Ben-Israel H, Kleinberger T. Adenovirus and cell cycle control. Front Biosci 2002; 7: d1369-d1395.
53. Fukuda K et al. E1A, E1B double-restricted adenovirus for oncolytic gene therapy of gallbladder cancer. Cancer Res 2003; 63: 4434-4440.
54. Holm PS et al. Multidrug-resistant cancer cells facilitate E1-independent adenoviral replication: impact for cancer gene therapy. Cancer Res 2004; 64: 322-328.
55. Kim E et al. Ad-mTERT-delta19, a conditional replication-competent adenovirus driven by the human telomerase promoter, selectively replicates in and elicits cytopathic effect in a cancer cell-specific manner. Hum Gene Ther 2003; 14: 1415-1428.
56. Wold W. Adenovirus Methods and Protocols. Humana Press Inc.: Totowa, NJ, 1998.
57. Grines CL et al. Angiogenic gene therapy (AGENT) trial in patients with stable angina pectoris. Circulation 2002; 105: 1291-1297.